Paysign, Inc. (PAYS)
| Market Cap | 556.60M +96.3% |
| Revenue (ttm) | 109.85M +46.7% |
| Net Income | 20.29M +168.4% |
| EPS | 0.33 +154.0% |
| Shares Out | 56.85M |
| PE Ratio | 29.61 |
| Forward PE | 27.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,539,263 |
| Open | 9.87 |
| Previous Close | 10.06 |
| Day's Range | 9.22 - 10.60 |
| 52-Week Range | 3.08 - 16.16 |
| Beta | 0.87 |
| Analysts | Buy |
| Price Target | 14.81 (+51.28%) |
| Earnings Date | Nov 9, 2026 |
About PAYS
Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts a... [Read more]
Financial Performance
In 2025, Paysign's revenue was $82.03 million, an increase of 40.50% compared to the previous year's $58.38 million. Earnings were $7.55 million, an increase of 97.90%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for PAYS stock is "Buy." The 12-month stock price target is $14.81, which is an increase of 51.28% from the latest price.
News
Paysign price target lowered to $14 from $15 at DA Davidson
DA Davidson lowered the firm’s price target on Paysign (PAYS) to $14 from $15 and keeps a Buy rating on the shares. The company reported strong Q3 results with 43%…
Paysign price target raised to $15.25 from $14 at Ladenburg
Ladenburg analyst Jon Hickman raised the firm’s price target on Paysign (PAYS) to $15.25 from $14 and keeps a Buy rating on the shares after revising earnings model for 2026…
Paysign downgraded to Hold from Buy at Maxim
Maxim downgraded Paysign (PAYS) to Hold from Buy.
Paysign pullback an ‘overreaction,’ sets up buying opportunity, says Barrington
Barrington reiterated an Outperform rating and $15 price target on Paysign (PAYS), saying the company’s Q3 financial results were better than expected. Of note, the only blemish on the quarter…
Paysign reports Q3 EPS 11c, consensus 9c
Reports Q3 revenue $30.8M, consensus $29.0M. “This was a strong quarter, with patient affordability continuing to compound,” said Mark Newcomer, President and CEO of Paysign (PAYS). “We expanded to 16...
Paysign sees FY26 EPS 37c-38c, consensus 32c
Sees FY26 revenue $114M-$117M, consensus $114.7M. Sees FY26 adjusted EBITDA $38.5M-$40.0M.
Lake Street keeps Buy on Paysign after Q3 beat
Lake Street reiterates a Buy rating and $15 price target on Paysign (PAYS) after the company beat on both top and bottom lines in Q3 and raised its full-year profitability…
Paysign Earnings Call Transcript: Q3 2026
Q3 revenue rose 43% YoY to $30.8M, with patient affordability more than doubling and margins expanding. FY26 revenue guidance held at $114M-$117M while profitability outlook improved, despite a planned 113-center plasma transition.
Paysign Earnings release: Q3 2026
Paysign released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Paysign Quarterly report: Q3 2026
Paysign has published its Q3 2026 quarterly earnings report on November 9, 2026.
Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a provider of patient affordability offerings, donor compensation solutions, engagement and management platforms and integrated payment ...
Paysign to Host Third Quarter 2026 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated p...
Paysign price target raised to $15 from $12 at DA Davidson
DA Davidson raised the firm’s price target on Paysign (PAYS) to $15 from $12 and keeps a Buy rating on the shares. After digging further into the Patient Affordability niche…
Paysign price target raised to $15 from $13 at Lake Street
Lake Street raised the firm’s price target on Paysign (PAYS) to $15 from $13 and keeps a Buy rating on the shares. After having hosted Paysign at the firm’s BIG10…
Paysign Transcript: 17th Annual Midwest IDEAS Conference
The company operates leading plasma payments and pharma co-pay businesses, achieving strong double-digit revenue and margin growth. Patient affordability programs are expanding rapidly, with significant cost savings for clients and a robust pipeline. Plasma payments remain a cash-generating core, funding further growth.
Paysign, Inc. to Present at the 17th Annual Midwest IDEAS Investor Conference
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated p...
Paysign Slides: Investor presentation
Paysign has posted slides in relation to its latest quarterly earnings report, which was published on August 17, 2026.
Paysign price target raised to $15 from $11 at Barrington
Barrington analyst Gary Prestopino raised the firm’s price target on Paysign (PAYS) to $15 from $11 and keeps an Outperform rating on the shares. The company reported a better than…
Paysign Slides: Corporate presentation
Paysign has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Paysign price target raised to $12 from $9 at DA Davidson
DA Davidson raised the firm’s price target on Paysign (PAYS) to $12 from $9 and keeps a Buy rating on the shares.
Paysign price target raised to $13 from $11 at Lake Street
Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $13 from $11 and keeps a Buy rating on the shares. Q2 marked “another step-change in…
Paysign raises FY26 EPS view to 57c-61c from 21c-26c, consensus 33c
Raises FY26 revenue view to $114M-$117M from $106.5M-$110.5M, consensus $108.55M.
Paysign Earnings Call Transcript: Q2 2026
Record Q2 results with 48% revenue growth and 113% higher adjusted EBITDA, driven by Patient Affordability and plasma recovery. Full-year guidance raised, margins expanded, and platform scalability demonstrated by rapid program launches and strong win rates.
Paysign Earnings release: Q2 2026
Paysign released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Paysign Quarterly report: Q2 2026
Paysign has published its Q2 2026 quarterly earnings report on August 5, 2026.